<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03937245</url>
  </required_header>
  <id_info>
    <org_study_id>EurobactII</org_study_id>
    <nct_id>NCT03937245</nct_id>
  </id_info>
  <brief_title>Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care</brief_title>
  <acronym>EurobactII</acronym>
  <official_title>Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care: the Eurobact II Multinational Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Outcome Rea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Society of Intensive Care Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Society of Clinical Microbiology and Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Outcome Rea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eurobact II will investigate the mortality and morbidity of hospital-acquired blood stream&#xD;
      infections in patients treated in intensive care units (ICU). It will investigate the effects&#xD;
      of the micro-organism and its characteristics, such as type and resistance to antibiotics on&#xD;
      the infection and its consequences. It will also investigate the effects of the antibiotics&#xD;
      and other treatments on survival of patients. Eurobact II will include patients from multiple&#xD;
      ICUs in multiple countries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eurobact II is a multinational multicentre cohort study that will include patients with&#xD;
      hospital-acquired blood stream infections (HA-BSI) treated in ICUs around the globe. It will&#xD;
      provide with an update of the epidemiology of HA-BSI since the Eurobact I study. It is&#xD;
      designed to investigate the effects of HA-BSI on mortality at day 28. To describe the&#xD;
      determinants of outcomes of HA-BSI, specifically the effects of the source of infection, the&#xD;
      microorganism, the characteristics of antimicrobial therapy and of source control. It will&#xD;
      investigate patient specific and organizational factors and will describe the determinants of&#xD;
      management of HA-BSI in ICUs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 30, 2019</start_date>
  <completion_date type="Actual">June 3, 2021</completion_date>
  <primary_completion_date type="Actual">June 2, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>28 Days</target_duration>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Vital status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress of organ failures</measure>
    <time_frame>7 days</time_frame>
    <description>Assessed by the components of the SOFA score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days free or organ supportive therapy</measure>
    <time_frame>28 days</time_frame>
    <description>Days free of renal replacement therapy, mechanical ventilation, vasopressors, intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical cure</measure>
    <time_frame>7 days, 28 days</time_frame>
    <description>As evaluated by the treating clinician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological cure</measure>
    <time_frame>7 days, 28 days</time_frame>
    <description>Presence of persisting or relapsing blood stream infection</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3058</enrollment>
  <condition>Bacteremia</condition>
  <condition>Sepsis</condition>
  <condition>Hospital Acquired Condition</condition>
  <condition>Resistance Bacterial</condition>
  <arm_group>
    <arm_group_label>HA-BSI</arm_group_label>
    <description>Patients with HA-BSI treated in an ICU</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a HA-BSI treated in an ICU&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 Years.&#xD;
&#xD;
          -  Hospital Acquired Bloodstream Infection (HA-BSI).&#xD;
&#xD;
          -  Treated in the ICU.&#xD;
&#xD;
               -  ICU acquired OR&#xD;
&#xD;
               -  Hospital acquired prior to ICU admission&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients that had a positive blood culture in the hospital and transferred to ICU for&#xD;
             a different reason than specific treatment of the causes or consequences of HA-BSI.&#xD;
&#xD;
          -  Previous inclusion in the study.&#xD;
&#xD;
               -  HA-BSI is defined as a positive blood culture (BC) sampled after 48 hours&#xD;
                  following hospital admission.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexis Tabah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICU, Redcliffe Hospital, Faculty of Medicine, UQ, Brisbane, QLD, Australia.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Francois Timsit, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medical and infectious diseases ICU, Bichat hospital, IAME U 1137,Paris,France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Redcliffe Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4020</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reanimation Medicale et Infectieuse-Hopital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.eurobact.org</url>
    <description>Eurobact II website</description>
  </link>
  <reference>
    <citation>Tabah A, Koulenti D, Laupland K, Misset B, Valles J, Bruzzi de Carvalho F, Paiva JA, Cakar N, Ma X, Eggimann P, Antonelli M, Bonten MJ, Csomos A, Krueger WA, Mikstacki A, Lipman J, Depuydt P, Vesin A, Garrouste-Orgeas M, Zahar JR, Blot S, Carlet J, Brun-Buisson C, Martin C, Rello J, Dimopoulos G, Timsit JF. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med. 2012 Dec;38(12):1930-45. doi: 10.1007/s00134-012-2695-9. Epub 2012 Sep 26.</citation>
    <PMID>23011531</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 1, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hospital-acquired infection</keyword>
  <keyword>Blood stream infection</keyword>
  <keyword>Bacteremia</keyword>
  <keyword>Intensive care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Iatrogenic Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03937245/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

